DRugwatch BlogRSS 2.0

DRugwatch Blog > March 2012 > Napa Valley Uncorked: How to Sample Napa’s Wine Industry in Only a Day

Napa Valley Uncorked: How to Sample Napa’s Wine Industry in Only a Day

Contributor: Allison Thrower

Just an hour north of San Francisco, there lies a 35-mile-long respite from the real world, better known as the relatively relaxed, comparatively rural and definitively grape-oriented region of Napa Valley. Although wine production has been a staple of Napa’s economy since the 1800s, only in the last half century has Napa become a destination for international wine enthusiasts. In spite of an economic history pocked by failed mining operations, widespread grape vine disease and the 1920s prohibition era, the Napa wine industry has made an extraordinary comeback (thanks in large-part to Robert Mondavi’s efforts in burgeoning the region’s wine production in the 1960s). Napa is now responsible for 25% of California’s wine economy, and this is generally attributed to the area’s transformation into the epitome American wine country, drawing some 4-5 million annual visitors from around the globe.

Napa promises a leisurely detour for a weekend following, for example, the Competitive Landscape Seminar Series: Oncology in nearby San Francisco. Despite the time of year, the area still features spectacular scenery, quaint shopping and dining locales, mild weather and arguably some of the best wine in America, with the off-season perk of avoiding throngs of summer tourists. While you’ll never be able to explore all of the county’s 300-plus wineries, it is possible to get more than a taste of the culture (and viticulture) of this small but welcoming bit of Northern California in only the span of a day.

Artesa Vineyards & Winery
Starting from the city, cross the Golden Gate Bridge and take I-80 for a little over 50 miles; Artesa should be one of the first stops on any Napa Valley wine excursion. A long winding driveway meanders up the hill to the winery, passing sculptures, fountains and one of the best 360° views of the countryside around. An ultra-modern tasting room showcases the hilly panorama, where you can enjoy a four-wine tasting experience starting at $10, or jump for a cheese- or chocolate-pairing package for $45 and up. Estate tours are also available by appointment.

Far Niente
Although a multitude of vineyards branch off of Highway 29, you shouldn’t bypass the charming Far Niente Winery less than 20 miles north of Artesa. Far Niente is a refurbished pre-prohibition estate that showcases a southern-style winery and 13 acres of azalea-laden gardens, complemented by attentive and expert staff for the quintessential winery experience. Tours are by appointment only, but within that you are guided through the grounds and winery, including the classic car collection and historic wine aging caves. Be sure to try their signature dessert wine Dolce, a late-harvest blend of Semillon and Sauvignon Blanc grapes so delightful it’s earned the nickname “Liquid Gold of Napa Valley.”

St. Helena
Following the course on Highway 29 will take you straight through the town of St. Helena or “Napa Valley’s Main Street.” Quaint and hospitable, St. Helena doesn’t offer an excuse to let your wine palette breathe with lunch in one of the many home-grown restaurants determined to celebrate the region’s core industry. Peruse the area’s locally owned stores for unique shopping options that include art galleries, artisan bakeries and boutiques.

Sterling Vineyards
Sterling resides farthest north in Napa’s Calistoga region but is still a must-visit winery on your trip. Access for visitors is only granted via an aerial tram, providing breathtaking views of the vineyards and surrounding mountain ranges. As visitors rise into view of the winery, it’s evident that the estate’s architecture does not shy away from Mediterranean influence, with stark white stucco walls and arched bell towers that house the historic bells of a 10th century London church. A $25 general admission includes a self-guided tour of the winery, assisted by interactive, motion-sensitive televisions that lead you through the history of the vineyard, an overview of the wine making process and a tasting of five Sterling wines.

Capping off a relaxing day of scenic drives, food and of course wine can include any number of restaurant or night-life locations in and around the valley, but especially in the town proper. A number of resorts are located nearby Sterling Vineyards that feature the famous Calistoga natural hot springs, if you’d prefer a spa break. Or, if you’ve experienced your fill of wine and leisure, make the all-too short trip back to the city and reality.

So, if you are joining us in nearby San Francisco on March 8th for the Competitive Landscape Seminar Series: Oncology, why not extend your stay and sample some of the best wine in America.

Posted on: 3/1/2012 2:50:55 PM | with 1 comments

Tags: Allison Thrower, Conference Commentary, Just for Fun

Trackback URL: http://decisionresources.com/trackback/5a08bdd6-70d5-42ec-96c3-d745fdd379ba/Napa-Valley-Uncorked--How-to-Sample-Napa’s-Wine-Industry-in-Only-a-Day.aspx?culture=en-us

I'm a fanIn response to one of the above evirews: Seven Springs Winery does not bring in out of state grapes. I visit wineries all over the state, but visit this one often because it's close to home. I find the staff has a great knowledge of wine and are very helpful. The owner is normally around and he is a very nice man. We like to go for the live music on the weekends, it's always a varied crowd of all ages.The funny thing is, Casa De Loco DOES bring in out of state grapes, they are all from CA. The only MO wine they have is made by the winery in Rocheport, MO.
3/9/2012 6:16:21 AM

Leave comment Subscribe

What is the abbreviation for Accountable Care Organization?


rss twitter linkedin


DRugwatch Blog

Quick insight on intriguing drug market developments from Decision Resources’ analysts.

Recent posts

Post title:
The Budgetary Impact of Diabetic Comorbidities in Brazil and Mexico - How Little is Being Done to Measure and Control It
Post date:
8/31/2015 10:48:39 AM
Post Summary:
The type 2 diabetes (T2D) therapy market is often tied to a high commercial opportunity. Indeed, when we look at key Latin American markets such as Brazil and Mexico -- each with over 14 million prevalent cases of T2D and growing, and Mexico with one of the highest prevalence rates in the world -- it is unsurprising that Brazil’s and Mexico’s total pharmaceutical market for type 2 diabetes rival the size of some of the more mature markets.

Post title:
2015 ESC Congress in London – Overview of Upcoming Hot Line Sessions
Post date:
7/2/2015 11:57:46 PM
Post Summary:
Conor WalshContributor: Conor Walsh M.Sc., Ph.D.
Topics: Conference Commentary, Cardiovascular

This year’s ESC congress will take place in the Excel Exhibition Centre in London, United Kingdom. The spotlight this year is “environment and the heart,” highlighting the many different kinds of interactions between the environment and cardiovascular diseases.

Post title:
FDA Approval for The Medicines Company’s Intravenous Antiplatelet Kengreal
Post date:
6/23/2015 1:22:54 PM
Post Summary:
Conor WalshContributors: Conor Walsh, M.Sc., Ph.D.
Topics: Cardiovascular

On June 22nd, 2015 the U.S. FDA approved Kengreal (cangrelor), the Medicines Company’s intravenous antiplatelet drug for use “as an adjunct to percutaneous coronary intervention (PCI) for reducing the risk of periprocedural myocardial infarction, repeat coronary revascularization, and stent thrombosis in patients in who have not been treated with a P2Y12 platelet inhibitor and are not being given a glycoprotein IIb/IIIa inhibitor.”

Post title:
Hematological Malignancies: Are Immune Checkpoint Inhibitors Checking-in?
Post date:
6/17/2015 9:32:42 AM
Post Summary:
Contributor: Dana Gheorghe, Ph.D
: Conference Commentary, Oncology

Recent years have seen an added emphasis on the relationship between cancer and the activity of the immune system. Novel agents that aim to harness the immune system have already been approved in the U.S. for solid tumors (Bristol-Myers Squibb/Ono Pharmaceutical’s Opdivo [nivolumab] for NSCLC and malignant melanoma, and Merck & Co.’s Keytruda [pembrolizumab] for malignant melanoma), and are in development for a plethora of other oncology indications. Most of the development has been targeted towards solid tumors, but the potential of immune checkpoint inhibitors in hematological malignancies is becoming increasingly evident.

Post title:
Cardiovascular Outcomes Trials Answer Long-Asked Questions – But New Questions Arise
Post date:
6/12/2015 10:26:05 AM
Post Summary:
Contributor: Eamonn O'Connor, Ph.D.

The recent American Diabetes Association’s 75th Scientific Sessions in Boston saw the release of data from the ELIXA cardiovascular outcomes trial (CVOT) for lixisenatide (Sanofi/Zealand Pharma’s Lyxumia), the first such trial completed for the GLP-1 receptor agonist drug class. However, it was the publication of the data from the CVOT for sitagliptin (Merck’s Januvia/Ono’s Glactiv), known as TECOS1, that was most eagerly anticipated; this is because the previous CVOTs for saxagliptin (AstraZeneca’s Onglyza) and alogliptin (Takeda/Furiex’s Nesina/Vipidia) had raised significant concerns about a potential risk for increased rates of hospitalization due to heart failure. The results from TECOS therefore, were viewed as pivotal as to whether this risk was a feature specific to the DPP-IV inhibitor drug class.

Decision Resources Group brands include: